binimetinib

Introduction

FDA approved June 2018

Indications

• for use in combination with encorafenib for the treatment of patients with unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma

Dosage

• 15 mg PO

Tablets: 15 mg tablets

Mechanism of action

• selective inhibitor of MEK

More general terms

• small inhibitory antineoplastic agent (ib drug)

Component of

• binimetinib/encorafenib

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=10288191